Zhuhai Trinomab Pharmaceutical Co., Ltd.

688806 · SHG · Healthcare / Drug Manufacturers - Specialty & Generic

21.97CNY-1.16 (-5.02%)

Price History

Full chart

Market Stats

Previous Close23.13

Open23.18

Day Range21.86 – 23.49

52-Week Range19.84 – 52.52

Volume4.28M

Market Cap10.55B

P/E (TTM)0.00

Forward P/E0.00

EPS-1.12

Dividend Yield0.00%

50-Day Avg24.40

200-Day Avg25.42

About

Zhuhai Trinomab Pharmaceutical Co., Ltd., a biopharmaceutical company, researches, develops, and commercializes therapeutics for infectious diseases and pain-related or autoimmune disorders. The company's product includes Siltartoxatug Injection (TNM002), a recombinant anti-tetanus toxin monoclonal antibody that neutralizes the toxic effects that target the human neural system. The company was founded in 2015 and is based in Zhuhai, China.

Company Details

SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
CEOMr. Huaxin Liao
Employees843
HeadquartersZhizao Street, Zhuhai, China, 519090, China
Websitehttps://www.trinomab.com

Leadership

Mr. Huaxin LiaoCo-Founder, Chairman & CTO · b. 1953
Mr. Weihong ZhengCo-Founder, Vice-Chairman & GM · b. 1973
Mr. Xiaoming ChiFinancial Director · b. 1970
Ms. Wanmei WangChief Medical Officer, Senior VP & Director · b. 1964
Mr. Xiaohui YuanSecretary of the Board & Assistant GM · b. 1980
Mr. Ming Li ChengVice President of Chemical Production Control · b. 1954

Financials

Income Statement

Currency: CNY	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Revenue	4.34M	0	15.06M	51.22M
Growth (%)	-	-100.00%	-	+240.23%
Cost of Revenue	2.78M	-	15.28M	28.94M
Gross Profit	1.56M	0	-225.77K	22.29M
Gross Margin	35.95%	-	-1.50%	43.51%
Operating Expense	368.97M	465.59M	509.30M	601.02M
Operating Income	-367.41M	-465.59M	-509.52M	-578.73M
Operating Margin	-8466.02%	-	-3384.21%	-1129.78%
EBITDA	-378.92M	-406.11M	-465.55M	-543.58M
EBITDA Margin	-8731.41%	-	-3092.14%	-1061.17%
Net Income	-428.67M	-446.46M	-514.77M	-601.32M
Net Income Margin	-9877.70%	-	-3419.04%	-1173.88%
R&D	322.51M	392.81M	425.03M	344.12M
R&D as % of Total Revenue	7431.54%	-	2823.04%	671.79%
Interest Expense	23.05M	6.26M	12.23M	18.00M
Interest Expense % of Total Revenue	531.17%	-	81.21%	35.14%

Balance Sheet

Currency: CNY	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Assets	1.15B	991.93M	933.30M	978.50M
Total Liabilities	190.49M	279.63M	550.25M	862.84M
Total Equity	960.96M	712.30M	383.05M	103.66M
Cash	758.35M	594.72M	559.41M	515.37M

Cash Flow

Currency: CNY	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Operating Cash Flow	-302.49M	-309.09M	-369.29M	-580.01M
Capital Expenditure	60.35M	20.86M	16.26M	22.35M
Free Cash Flow	-362.84M	-329.96M	-385.55M	-602.36M
Dividends Paid	4.53M	3.62M	8.57M	17.20M
FCF to OCF	119.95%	106.75%	104.40%	103.85%
Dividend Paid to FCF	-1.25%	-1.10%	-2.22%	-2.86%

Key Statistics & Ratios

Market Cap10.55B

Enterprise Value10.09B

Trailing P/E0.00

Forward P/E0.00

Price / Sales60.14

Price / Book12.50

EPS-1.12

Book Value1.90

Revenue (TTM)175.37M

Gross Profit (TTM)121.82M

EBITDA-410.77M

Profit Margin-256.84%

Operating Margin-108.60%

Return on Equity0.00%

Return on Assets0.00%

Shares Outstanding460.55M

Shares Float201.72M

Dividend Yield0.00%

Dividend Rate0.00

Payout Ratio0.00%